Compare Remitly Global Inc (RELY) vs 10X Genomics Inc (TXG) Price & Performance

RELY trades at $23.83, down 1.24% on the day, with a bullish technical signal from moving averages. The company has demonstrated a strong turnaround, achieving profitability in 2025 with net income of $67.93 million after years of losses. Revenue growth is robust, reaching $1.64 billion in 2025, with positive cash flow from operations of $325.08 million. Recent news highlights expansion, including a new license in the UAE and raised full-year guidance for 2026.

The outlook is positive, driven by accelerating revenue growth, market share gains in the remittance sector, and a clear path to sustained profitability. Key risks include intense competition from established payment giants and execution challenges in international expansion. With a consensus analyst price target of $28.50 implying significant upside, the stock presents a growth opportunity, though investors should be mindful of its premium valuation multiples.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.